Related Experiment Video
Updated: Jan 21, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A Weinberg1, Joanne Xiu2, Michael R Lindberg1
1Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Background:
Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC) are frequently grouped together in clinical trials despite differences in tumor biology.
Methods:
To further investigate tumor biology differences, we profiled 1,502 BTCs using next-generation sequencing (NGS), immunohistochemistry, in situ hybridization, and RNA sequencing.
Results:
IHCCs had higher rates of IDH1, BAP1, and PBRM1 mutations and FGFR2 fusions; EHCCs had higher rates of KRAS, CDKN2A, and BRCA1 mutations; and GBCs had higher rates of homologous recombination repair deficiency and Her2/neu overexpression and amplification. IHCCs and GBCs had higher rates of potential positive predictive biomarkers for immune checkpoint inhibition (PD-L1 expression, high microsatellite instability, and high tumor mutational burden) than EHCCs.
Conclusions:
These findings support clinical molecular profiling of BTCs to inform potential therapeutic selection and clinical trial design based on the primary tumor's site of origin within the biliary tree.
Insights
Molecular profiling reveals distinct genetic differences across biliary tract cancer subtypes. These findings support personalized treatment strategies and clinical trial design based on tumor origin for better outcomes in biliary cancers.
Area of Science:
- Oncology
- Genomics
- Cancer Biology
Background:
- Biliary tract cancers (BTCs) are rare, aggressive malignancies with limited treatment options.
- Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC) are often studied together despite biological differences.
Purpose of the Study:
- To investigate the distinct tumor biology of IHCC, EHCC, and GBC.
- To identify potential therapeutic targets and biomarkers for different BTC subtypes.
Main Methods:
- Profiling of 1,502 BTCs using next-generation sequencing (NGS), immunohistochemistry, in situ hybridization, and RNA sequencing.
Main Results:
- IHCCs showed higher rates of IDH1, BAP1, PBRM1 mutations and FGFR2 fusions.
- EHCCs had increased KRAS, CDKN2A, and BRCA1 mutations.
- GBCs exhibited higher rates of homologous recombination repair deficiency and Her2/neu amplification. IHCCs and GBCs had more biomarkers for immune checkpoint inhibition than EHCCs.
Conclusions:
- Significant molecular differences exist between IHCC, EHCC, and GBC.
- Clinical molecular profiling of BTCs is crucial for guiding therapeutic selection.
- Findings support tailored clinical trial design based on the primary tumor's location within the biliary tree.
Related Concept Videos
02:00Molecular Models
03:10Molecular Compounds: Formulas and Nomenclature
03:51Molecular Orbital Theory II
02:54Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
02:35Molecular Orbital Theory I
03:37Molecular Shape and Polarity